Drugs / ABT-652
last change May 2012 re-read 2 minutes ago

ABT-652

Developed for
osteoarthritis, knee · diabetic neuropathy · sleep disorder
Investigated by
AbbVie · Abbott

Trials 4 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01124851 Aug 2010 → Apr 2011 sleep disorder Abbott Completed No outcome recorded
Phase 23 trials
Phase 2 NCT01579279 Apr → May 2012 diabetic neuropathy AbbVie Terminated No outcome recorded
Phase 2 NCT01444365 Oct 2011 → Apr 2012 osteoarthritis, knee AbbVie Completed No outcome recorded
Phase 2 NCT01207115 Sep 2010 → May 2011 osteoarthritis, knee AbbVie Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as ABT-652 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01207115
3

NCT01444365

NCT01579279

NCT01124851

Route Oral “ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days” NCT01124851